Compare · CAI vs ILMN
CAI vs ILMN
Side-by-side comparison of Caris Life Sciences Inc. (CAI) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAI and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $23.91B, about 24.6x CAI ($971.9M).
- Over the past year, CAI is down 39.2% and ILMN is up 88.3% - ILMN leads by 127.5 points.
- ILMN has been more active in the news (22 items in the past 4 weeks vs 11 for CAI).
- ILMN has more recent analyst coverage (25 ratings vs 15 for CAI).
- Company
- Caris Life Sciences Inc.
- Illumina Inc.
- Price
- $16.97+5.08%
- $160.01+1.19%
- Market cap
- $971.9M
- $23.91B
- 1M return
- +5.11%
- +12.73%
- 1Y return
- -39.22%
- +88.29%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 11
- 22
- Recent ratings
- 15
- 25
Caris Life Sciences Inc.
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CAI
- Caris Life Sciences Announces Share Repurchase Program
- Caris Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Poste George was granted 1,600 shares, increasing direct ownership by 10% to 17,729 units (SEC Form 4)
- Director Knowles Jonathan Kenneth Charles was granted 1,600 shares, increasing direct ownership by 0.52% to 308,979 units (SEC Form 4)
- Wolfe Research resumed coverage on Caris Life Sciences
- Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
- Officer Denton John Russel covered exercise/tax liability with 6,047 shares, decreasing direct ownership by 3% to 181,515 units (SEC Form 4)
- Officer Power Luke Thomas covered exercise/tax liability with 9,771 shares, decreasing direct ownership by 6% to 153,771 units (SEC Form 4)
- Officer Brille Brian J covered exercise/tax liability with 13,987 shares, decreasing direct ownership by 6% to 230,303 units (SEC Form 4)
- President Spetzler David Baxley covered exercise/tax liability with 13,856 shares, decreasing direct ownership by 3% to 530,083 units (SEC Form 4)
Latest ILMN
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits